Careers  |  Sign In  |  Register

Melanoma Content Hub

Patients in CheckMate 067 Demonstrate Durable Complete Responses

Georgina V. Long, BSc, PhD, MBBS, co-medical director of Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital at the University of Sydney, discusses patient outcomes in the CheckMate 067 trial, featuring a combined treatment of nivolumab and ipilimumab for melanoma.

While 80% of patients retain complete response for five years, Dr. Long recognizes approximately 20% of the trial cohort, often those with poor prognostic features, such as M1c and noncutaneous melanoma, regress by year five. For these patients, researchers are exploring treatment duration and corticosteroid administration to optimize patient response.

Learn more by clicking here.